RETRACTABLE TECHNOLOGIES INC

Listed Company
RVPCIK 0000946563NYSENon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusTexasFY ends Dec 31
Period
FY 2025
Revenue
$38.27M
Net Income
$-12.57M
Total Assets
$142.63M
Equity
$74.38M
Shares Out
29.94M
Op. Cash Flow
$-7.06M

Business

Retractable Technologies Inc manufactures and markets safety medical products, primarily retractable syringes and needles, for the healthcare industry. Its main products include injection devices marketed under the VanishPoint®, Patient Safe®, and EasyPoint® brands, featuring retractable needle safety and low dead space designs. The company operates manufacturing facilities domestically and uses international manufacturers, with operations governed in part by a government Technology Investment Agreement supporting expanded capacity. Products are sold primarily to healthcare providers through U.S. general-line and specialty distributors, international distributors, group purchasing organizations, and a national direct marketing network.

Summary from filing dated 2025-03-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts
ConceptTrend
FY 2025
2025-12-31
FY 2024
2024-12-31
FY 2023
2023-12-31
FY 2022
2022-12-31
FY 2021
2021-12-31
Sales, net38334495188
Total cost of sales3834346793
Gross profit (loss)47,046−192895
Sales and marketing76654
Research and development675,567673,944581,172525,727901,381
General and administrative1314142417
Impairment of assets954,000
Total operating expenses2120212923
Loss from operations−21−21−11−852,97673
Other income - TIA6664425,158
Unrealized gain (loss) on debt and equity securities−511−112513,529
Gain on trading debt and equity securities66
Litigation proceeds2
Interest and other income547,361119,948266,467
Interest expense−87,904−122,500−152,166−170,651
Net loss before income taxes−12−4−9575
Provision (benefit) for income taxes291,2938−283,87019
Net loss−13−12−7556
Preferred Stock dividend requirements−230,444−230,444−231,946−232,444−241,703
Net loss applicable to common shareholders−13−12−7556
Basic loss per share−0.43−0.4−0.240.151.65
Diluted loss per share−0.43−0.4−0.240.151.63
Basic (in shares)3030303334
Diluted (in shares)3030303334

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro